JP2015536995A5 - - Google Patents

Download PDF

Info

Publication number
JP2015536995A5
JP2015536995A5 JP2015541981A JP2015541981A JP2015536995A5 JP 2015536995 A5 JP2015536995 A5 JP 2015536995A5 JP 2015541981 A JP2015541981 A JP 2015541981A JP 2015541981 A JP2015541981 A JP 2015541981A JP 2015536995 A5 JP2015536995 A5 JP 2015536995A5
Authority
JP
Japan
Prior art keywords
container
long
budesonide
term stable
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015541981A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015536995A (ja
JP6423353B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/069449 external-priority patent/WO2014074995A1/en
Publication of JP2015536995A publication Critical patent/JP2015536995A/ja
Publication of JP2015536995A5 publication Critical patent/JP2015536995A5/ja
Application granted granted Critical
Publication of JP6423353B2 publication Critical patent/JP6423353B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015541981A 2012-11-09 2013-11-11 潰瘍性大腸炎の治療のための長期安定性を有する浣腸剤組成物 Expired - Fee Related JP6423353B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261724678P 2012-11-09 2012-11-09
US61/724,678 2012-11-09
PCT/US2013/069449 WO2014074995A1 (en) 2012-11-09 2013-11-11 Enema composition for treatment of ulcerative colitis having long term stability

Publications (3)

Publication Number Publication Date
JP2015536995A JP2015536995A (ja) 2015-12-24
JP2015536995A5 true JP2015536995A5 (enExample) 2016-12-22
JP6423353B2 JP6423353B2 (ja) 2018-11-14

Family

ID=50682294

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015541981A Expired - Fee Related JP6423353B2 (ja) 2012-11-09 2013-11-11 潰瘍性大腸炎の治療のための長期安定性を有する浣腸剤組成物

Country Status (8)

Country Link
US (2) US8809308B2 (enExample)
EP (2) EP3181120A1 (enExample)
JP (1) JP6423353B2 (enExample)
AU (1) AU2013342069B2 (enExample)
CA (1) CA2891090A1 (enExample)
ES (1) ES2622372T3 (enExample)
MX (1) MX2015005837A (enExample)
WO (1) WO2014074995A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8916546B2 (en) 2003-08-29 2014-12-23 Therapeutic Research Llc Materials and methods for treatment and diagnosis of disorders associated with oxidative stress
EP3181120A1 (en) * 2012-11-09 2017-06-21 Scidose LLC Enema composition for treatment of ulcerative colitis having long term stability
EA201791686A8 (ru) 2015-01-26 2018-10-31 Др. Фальк Фарма Гмбх Клизма для ректального введения
WO2018122086A1 (en) * 2016-12-28 2018-07-05 Dr. Falk Pharma Gmbh Enema for rectal application
PL3870226T3 (pl) * 2018-10-24 2023-12-27 Ferring B.V. Mukoadhezyjne kompozycje farmaceutyczne kortykosteroidów

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4211777A (en) 1977-11-25 1980-07-08 Fisons Limited Compositions comprising a compound having sodium cromoglycate activity and aminosalicylic acid
WO1981002671A1 (en) 1980-03-20 1981-10-01 Ferring Farma Lab Pharmaceutical composition and method for the treatment of colitis ulcerosa and crohn's disease by oral administration
US4657900A (en) 1983-09-27 1987-04-14 Rowell Laboratories Pharmaceutical article of manufacture comprising a bisulfite stabilized aqueous solution of 5-aminosalicylic acid and method
EP0382066A3 (de) 1989-02-09 1992-01-08 ASTA Medica Aktiengesellschaft Verwendung von Dihydroliponsäure als Analgetikum, Antiphlogistikum und/oder Zytoprotektivum
GB8909559D0 (en) 1989-04-26 1989-06-14 Smith Kline French Lab Pharmaceutical compositions
US5378470A (en) 1989-07-25 1995-01-03 Henning Berlin Gmbh Rectally administered pharmaceutical preparation
JPH03169813A (ja) 1989-11-09 1991-07-23 Asta Pharma Ag 細胞保護作用を有する疼痛及び炎症性疾患及び/又はレトロウイルスに起因する病気の治療用医薬並びにその製法
DE4218572A1 (de) 1992-06-05 1993-12-09 Asta Medica Ag Synergistische Kombination von Arzneimitteln enthaltend als Wirkstoff alpha-Liponsäure, Dihydroliponsäure, deren Metaboliten sowie die oxidierten und reduzierten Enantiomere der alpha-Liponsäure wie die R-alpha-Liponsäure oder S-alpha-Liponsäure sowie Metaboliten der alpha-Liponsäure mit den Vitaminen A, B1-6, B12, C und E
US5569670A (en) 1992-06-05 1996-10-29 Asta Medica Aktiengesellschaft Combination medications containing alpha-lipoic acid and related
US8178516B2 (en) 1992-06-30 2012-05-15 Sylvan Labs, LLC Compositions and method for treatment of chronic inflammatory diseases
US6444221B1 (en) 1992-06-30 2002-09-03 Howard K. Shapiro Methods of treating chronic inflammatory diseases using carbonyl trapping agents
US20050090553A1 (en) 1992-06-30 2005-04-28 Shapiro Howard K. Compositions and method for treatment of chronic inflammatory diseases
US5563131A (en) 1994-08-04 1996-10-08 Pherin Corporation Pregnane steroids as neurochemical initiators of change in human hypothalamic function and related pharmaceutical compositions and methods
DE4446891A1 (de) * 1994-12-27 1996-07-04 Falk Pharma Gmbh Stabile wäßrige Budesonid-Lösung
DE19509806A1 (de) 1995-03-21 1996-09-26 Basf Ag Lagerstabile Arzneiformen
US5817630A (en) 1997-03-18 1998-10-06 Austin Nutriceutical Corporation Glutathione antioxidant eye drops
US6197749B1 (en) 1997-10-29 2001-03-06 Ajinomoto Co., Inc. Method of suppressing immune responses by reducing intracellular content of glutathione in macrophages and monocytes
WO1999055326A1 (en) 1998-04-30 1999-11-04 Vit-Immune, L.C. Method of treatment of glutathione deficient mammals
AR042572A1 (es) 1999-04-02 2005-06-29 Sod Conseils Rech Applic Derivados de acido lipoico, procedimiento para su preparacion, medicamentos y composiciones farmaceuticas que los contienen y utilizacion de dichos derivados para la preparacion de los referidos medicamentos
US6664287B2 (en) 2000-03-15 2003-12-16 Bethesda Pharmaceuticals, Inc. Antioxidants
EP1172110A3 (de) 2000-07-07 2003-09-17 Basf Aktiengesellschaft Verwendung von Liponsäure zur Verbesserung der Bioverfügbarkeit von Mineralsalzen
AU2002256507A1 (en) 2001-05-09 2002-11-18 Novartis Ag Methods for selective immunomodulation using pimecrolimus
US20030235571A1 (en) 2002-06-19 2003-12-25 Gabriel Gojon-Romanillos Systemic treatment of pathological conditions resulting from oxidative stress and/or redox imbalance
WO2004024868A2 (en) 2002-09-10 2004-03-25 National Jewish Medical And Research Center Product and process for liquefaction of mucus or sputum
US7157444B2 (en) 2002-12-21 2007-01-02 Deanna Jean Nelson Aminosalicylate derivatives for treatment of inflammatory bowel disease
WO2004071488A1 (en) 2003-02-04 2004-08-26 Chrysalis Technologies Incorporated Perfluorocarbon and hydrofluorocarbon formulations and methods of making and using same
SE0300480D0 (sv) 2003-02-21 2003-02-21 Astrazeneca Ab Novel compounds
EP1603556A2 (en) 2003-03-06 2005-12-14 Yissum Research Development Company Of The Hebrew University Of Jerusalem Sod mimic multifunctional compounds for treating inflammatory bowel disease
WO2005009510A2 (en) 2003-07-23 2005-02-03 The Regents Of The University Of California Penetration enhancer combinations for transdermal delivery
US8476233B2 (en) * 2003-08-29 2013-07-02 Therapeutic Research, Llc Methods for treatment for ulcerative colitis in mammals
US20100112088A1 (en) 2003-08-29 2010-05-06 Jay Pravda Materials and methods for treatment of disorders associated with oxidative stress
US8916546B2 (en) * 2003-08-29 2014-12-23 Therapeutic Research Llc Materials and methods for treatment and diagnosis of disorders associated with oxidative stress
US7312243B1 (en) 2003-08-29 2007-12-25 Jay Pravda Materials and methods for treatment of gastrointestinal disorders
US8318210B2 (en) * 2005-02-28 2012-11-27 Neos Therapeutics, Lp Compositions and methods of making sustained release liquid formulations
US20090220583A1 (en) * 2005-06-09 2009-09-03 Lena Pereswetoff-Morath Method and composition for treating inflammatory disorders
TWI435729B (zh) * 2005-11-09 2014-05-01 Combinatorx Inc 治療病症之方法,組合物及套組
US7842709B2 (en) 2006-09-08 2010-11-30 Ore Pharmaceuticals Inc. Method for treating inflammatory diseases of the digestive tract
US20080066739A1 (en) * 2006-09-20 2008-03-20 Lemahieu Edward Methods and systems of delivering medication via inhalation
KR101245604B1 (ko) * 2007-11-13 2013-03-21 메리테이지 파마, 인크. 코르티코스테로이드 조성물
US7750027B2 (en) 2008-01-18 2010-07-06 Oxagen Limited Compounds having CRTH2 antagonist activity
BRPI1014160A2 (pt) * 2009-04-10 2015-08-25 Abraxis Bioscience Llc Formulações de nanopartículas e aplicações das mesmas
EP3181120A1 (en) * 2012-11-09 2017-06-21 Scidose LLC Enema composition for treatment of ulcerative colitis having long term stability

Similar Documents

Publication Publication Date Title
JP2015536995A5 (enExample)
MY149622A (en) Pyrazoles as 11-beta-hsd-1
UA109421C2 (uk) Фармацевтична композиція, яка містить ліганди сигма-рецептора
JP2013518056A5 (enExample)
WO2009010416A3 (en) Inhibitors of 11b-hydroxysteroid dehydrogenase
WO2012015810A3 (en) Pharmaceutical compositions containing pemetrexed having extended storage stability
EA201600118A1 (ru) Жидкая водная фармацевтическая композиция с консервантами, содержащая этерифицированные производные циклодекстрина
JP2016510019A5 (enExample)
JP2010520246A5 (enExample)
JP2016512210A5 (enExample)
FI3817751T3 (fi) Vedettömän natriumtiosulfaatin formulaatioita
JP2008542237A5 (enExample)
PE20141048A1 (es) Combinacion que comprende umeclidinio y un corticosteroide
JP2017514924A5 (enExample)
TW200643013A (en) Pyrazoles
RU2016135952A (ru) Композиции ингибитора дофа-декарбоксилазы
JP2014518274A5 (enExample)
JP2009537554A5 (enExample)
JP2015537009A5 (enExample)
UA101407C2 (ru) Стабильная комбинированная фармацевтическая композиция амлодипина и бисопролола фумарат
JP6423353B2 (ja) 潰瘍性大腸炎の治療のための長期安定性を有する浣腸剤組成物
EA201490363A1 (ru) Новые составы на основе (триметоксифениламино)пиримидинилов
AR085273A1 (es) Formulacion liquida libre de propelente que comprende una droga antimuscarinica
RU2008147216A (ru) Жидкая лекарственная композиция
JP2017508004A5 (enExample)